An­a­lysts cheer as Ab­b­Vie pays $750M cash to al­ly it­self with Gen­mab on a pipeline of can­cer drugs, with bil­lions more ...

6 years ago
Deals

King Keytru­da floun­ders in an­oth­er piv­otal can­cer study. And that may spur doubts about Mer­ck­'s stay­ing pow­er

6 years ago
R&D

Go­ing where PRO­TACs can't, Ver­sant un­veils $50M bet on Car­olyn Bertozzi's LY­TAC tech — with a ris­ing star at the ...

6 years ago
Financing
Startups

Covid-19 roundup: Eu­rope is ‘weeks away’ from remde­sivir de­ci­sion; John Far­ley gets per­ma­nent gig as chief of FDA ...

6 years ago
Coronavirus

Re­gen­eron joins $100M round for DNAnexus and its cloud-com­put­ing DNA soft­ware

6 years ago
R&D
AI

Take­da-part­nered Evox signs up to $1.2B pact with Lil­ly; New liq­uid biop­sy com­pa­ny launch­es with $12M Se­ries A

6 years ago
News Briefing

Lean­ing on BD to re­vive weak pipeline, Lund­beck plans to cut up to 160 jobs in R&D re­struc­tur­ing

6 years ago
People
R&D

Sanofi sends a pair of gene ther­a­pies back to Ox­ford Bio­med­ica. Are they sal­vage­able?

6 years ago
Cell/Gene Tx

CSL Behring snaps up a close­ly-held biotech part­ner and its IL-6 drug — for trans­plant re­jec­tion

6 years ago
Deals

ARCH-backed Au­to­bahn launch­es with $76M to re­build myelin and re­verse MS

6 years ago
Financing
Startups

Lil­ly, In­cyte-al­lied Chi­nese drug­mak­er In­novent bags Roche as part­ner in deal that could yield bil­lions

6 years ago
Deals
China

Cap­i­tal­iz­ing Pablo II: The up­dat­ed IPO for Roy­al­ty Phar­ma in­cludes a $16.6B mar­ket cap and a chart-top­ping $2.2B ...

6 years ago
Financing

In­s­med's an­ti-in­flam­ma­to­ry drug wins break­through sta­tus; Ky­owa Kirin backs new fund from 4BIO Cap­i­tal

6 years ago
News Briefing

Nim­bus picks 4 pre­clin­i­cal tar­gets for the next chap­ter of its pi­o­neer­ing com­pu­ta­tion­al drug dis­cov­ery work

6 years ago
Discovery

Sarep­ta re­veals pos­i­tive re­sults in limb-gir­dle gene ther­a­py tri­al. What does that mean for DMD?

6 years ago
R&D
Cell/Gene Tx

Bio­phar­ma IPO boom yields buoy­ant biotech pub­lic de­buts

6 years ago
Financing

NIH — and some fa­mil­iar play­ers — back a PhII Alzheimer’s gam­ble in an­oth­er stab at the amy­loid hy­poth­e­sis

6 years ago
R&D

When times got tough, the bio­phar­ma in­dus­try hit the Zoom but­ton and kept things mov­ing at a multi­bil­lion-dol­lar clip

6 years ago
Deals

Months af­ter steer­ing a seizure res­cue ther­a­py to mar­ket, UCB bags an­oth­er promis­ing late-stage as­set for $125M ...

6 years ago
Deals

Covid-19 roundup: Yet more dos­es of the As­traZeneca-Ox­ford vac­cine; A sec­ond ran­dom­ized hy­drox­y­chloro­quine study ...

6 years ago
Coronavirus

Add ear gene ther­a­py com­pa­ny Ak­ou­os to the ever-grow­ing list of IPOs amid Covid-19

6 years ago
Financing
Startups

Does As­traZeneca CEO Pas­cal So­ri­ot re­al­ly want to merge with Gilead? A Bloomberg sto­ry sug­gests he was in­ter­est­ed — ...

6 years ago
Deals

Al­ny­lam sets up 3rd po­ten­tial RNAi ap­proval with a show­case of pos­i­tive lumasir­an da­ta

6 years ago
R&D

Leg­end fetch­es $424 mil­lion, emerges as biggest win­ner yet in pan­dem­ic IPO boom as shares soar

6 years ago
Financing
R&D
First page Previous page 834835836837838839840 Next page Last page
A service from the Financial Times